Advancing a novel product pipeline of neurology therapies
View Product PipelineAbout
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.
Our novel product pipeline addresses areas of high unmet medical need, with a focus on epilepsy.
Read MoreNews
Xenon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 9, 2022
Xenon Pharmaceuticals to Present at the 13th Annual Wedbush PacGrow Healthcare Conference
August 8, 2022
Xenon Pharmaceuticals to Present at the William Blair Biotech Focus Conference 2022
July 11, 2022
Product Pipeline
XEN496
for Orphan Pediatric Epilepsy (KCNQ2-DEE)
EPIK Clinical Trial
XEN1101
for Focal Onset Seizures (FOS)
X-TOLE2/3 Clinical Trial
XEN1101
for Primary Generalized Tonic-Clonic Seizures (PGTCS)
X-ACKT Clinical Trial
XEN1101
for Major Depressive Disorder (MDD)
X-NOVA Clinical trial
XEN1101
for MDD
Investigator-led Phase 2 POC study Collaboration with Mount Sinai
NBI-921352
for Rare Pediatric Epilepsy: SCN8A-DEE
Partnered with Neurocrine Biosciences
NBI-921352
for Focal-Onset Seizures in Adults
Partnered with Neurocrine Biosciences
PCRX301
for Post-Operative Pain
Partnered with Pacira BioSciences
Investors
Visit our Investor page for News Releases, Annual & Quarterly Reports, Webcasts & Events
View Investor Area
